Antigen presentation modulation

Antigen presentation modulation" does **not** refer to a single molecule, protein, or receptor. Instead, it describes the therapeutic strategy or process by which the way cells present antigens—typically via major histocompatibility complex (MHC) molecules—is altered in order to influence T cell responses[1][3]. Antigen presentation is essential for triggering adaptive immunity; professional antigen-presenting cells such as dendritic cells, macrophages, and B cells display processed peptide fragments on their surface using MHC class I or II molecules for recognition by T cell receptors[1][5]. Modulating this process can change how the immune system recognizes infected or malignant cells and is being explored as an approach in cancer immunotherapy and autoimmune disease treatment[3]. Drugs described as "antigen modulators," such as GRWD5769 from Grey Wolf Therapeutics, aim to alter intracellular processing so that different peptides are presented on MHC molecules at the cell surface. This can make tumor cells more visible—or less visible—to T lymphocytes depending on therapeutic intent[3]. However, there is no single canonical protein called "antigen presentation modulation"; rather, this term encompasses multiple molecular targets involved in antigen processing and loading onto MHC complexes. Because “antigen presentation modulation” does **not** correspond to an individual gene product or receptor but rather describes a broad biological mechanism/process involving many proteins (such as MHC class I/II molecules and their regulators), it should **not** be treated as a canonical drug target entry.

Modulation of antigen processing and presentation pathways to alter immune recognition[3]